Immunity Pharma's IPL344 demonstrated a 58-64% slower ALSFRS-R progression rate in ALS patients compared to matched historical controls, with statistical significance (p=0.034).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.